Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087048 · ClinicalTrials.gov registry record · Phase 2
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00087048 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT00087048, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well high-dose topotecan works as second-line therapy in treating patients with recurrent extensive-stage small cell lung cancer.
Interventions
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087048
The ClinicalTrials.gov registry entry for NCT00087048 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which topotecan hydrochloride is the first listed.
NCT00087048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087048 about?
NCT00087048 is a clinical study titled "Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well high-dose topotecan works as second-line therapy in treating patients with recurrent extensive-stage smal...
What is the current status of trial NCT00087048?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2004-04. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00087048?
The interventions under investigation include: topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00087048?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.